Pacira Pharmaceuticals Inc (PCRX.OQ)
PCRX.OQ on NASDAQ Stock Exchange Global Select Market
35.30USD
24 Apr 2018
35.30USD
24 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$35.30
$35.30
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
253,450
253,450
52-wk High
$52.45
$52.45
52-wk Low
$26.98
$26.98
Consensus Recommendations
Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
---|---|---|---|
Outperform | 0.06 | December | 25 Apr 2018 |
Analyst Recommendations and Revisions
1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
---|---|---|---|---|
(1) BUY | 3 | 3 | 3 | 3 |
(2) OUTPERFORM | 6 | 6 | 6 | 7 |
(3) HOLD | 9 | 9 | 9 | 8 |
(4) UNDERPERFORM | 0 | 0 | 0 | 0 |
(5) SELL | 1 | 1 | 1 | 1 |
No Opinion | 0 | 0 | 0 | 0 |
Mean Rating | 2.47 | 2.47 | 2.47 | 2.42 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
# of Estimates | Mean | High | Low | 1 Year Ago |
|
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 19 | 76.92 | 82.54 | 74.68 | 97.13 |
Quarter Ending Sep-18 | 19 | 76.55 | 80.16 | 70.90 | 101.17 |
Year Ending Dec-18 | 19 | 312.84 | 333.68 | 302.05 | 392.04 |
Year Ending Dec-19 | 19 | 364.46 | 423.44 | 314.70 | 485.60 |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 18 | 0.06 | 0.26 | -0.06 | 0.36 |
Quarter Ending Sep-18 | 18 | 0.05 | 0.29 | -0.04 | 0.47 |
Year Ending Dec-18 | 18 | 0.28 | 1.05 | -0.06 | 1.77 |
Year Ending Dec-19 | 18 | 1.09 | 2.17 | -0.28 | 3.07 |
LT Growth Rate (%) | 2 | 62.25 | 65.90 | 58.60 | 76.35 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
---|---|---|---|---|
SALES (in millions) | ||||
Quarter Ending Dec-17 | 79.32 | 79.08 | 0.24 | 0.31 |
Quarter Ending Sep-17 | 69.65 | 67.33 | 2.31 | 3.32 |
Quarter Ending Jun-17 | 73.43 | 70.93 | 2.49 | 3.40 |
Quarter Ending Mar-17 | 70.27 | 69.28 | 0.99 | 1.41 |
Quarter Ending Dec-16 | 73.07 | 72.90 | 0.17 | 0.23 |
Earnings (per share) | ||||
Quarter Ending Dec-17 | 0.10 | 0.38 | 0.28 | 297.49 |
Quarter Ending Sep-17 | -0.06 | 0.11 | 0.17 | -298.92 |
Quarter Ending Jun-17 | -0.05 | -0.11 | 0.06 | -127.74 |
Quarter Ending Mar-17 | -0.04 | -0.19 | 0.15 | -430.73 |
Quarter Ending Dec-16 | 0.01 | 0.09 | 0.08 | 587.02 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 76.92 | 76.92 | 76.68 | 78.63 | 97.13 |
Quarter Ending Sep-18 | 76.55 | 76.55 | 76.18 | 77.84 | 101.17 |
Year Ending Dec-18 | 312.84 | 312.84 | 309.97 | 320.28 | 392.04 |
Year Ending Dec-19 | 364.46 | 364.46 | 354.33 | 373.21 | 485.60 |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 0.06 | 0.06 | 0.04 | 0.08 | 0.36 |
Quarter Ending Sep-18 | 0.05 | 0.05 | 0.04 | 0.09 | 0.47 |
Year Ending Dec-18 | 0.28 | 0.28 | 0.20 | 0.50 | 1.77 |
Year Ending Dec-19 | 1.09 | 1.09 | 0.96 | 1.36 | 3.07 |
Estimates Revisions Summary
Last Week | Last 4 Weeks | |||
---|---|---|---|---|
Number Of Revisions: | Up | Down | Up | Down |
Revenue | ||||
Quarter Ending Jun-18 | 0 | 0 | 2 | 1 |
Quarter Ending Sep-18 | 0 | 0 | 4 | 1 |
Year Ending Dec-18 | 0 | 0 | 9 | 1 |
Year Ending Dec-19 | 0 | 0 | 9 | 1 |
Earnings | ||||
Quarter Ending Jun-18 | 0 | 0 | 1 | 2 |
Quarter Ending Sep-18 | 0 | 0 | 2 | 2 |
Year Ending Dec-18 | 0 | 0 | 6 | 1 |
Year Ending Dec-19 | 0 | 0 | 8 | 0 |
- BRIEF-Pacira Pharmaceuticals Reports Q4 GAAP EPS Of $0.11
- BRIEF-Pacira Says FDA committee Did Not Reach A Unanimous Decision For Exparel As A Nerve Block To Produce Regional Analgesia
- BRIEF-Pacira Pharmaceuticals Says FDA Advisory Committee To Review SNDA For Exparel
- BRIEF-Pacira Pharma says FDA Posts Briefing Documents For Advisory Meeting Reviewing SNDA For Exparel
- BRIEF-Wellstar And Pacira To Minimize Opioid Use Across Surgical Procedures